Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

516 De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP et al. An
ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine
lupus nephritis. Kidney Int 2004; 65: 846–859.
517 MacKinnon M, Shurraw S, Akbari A, Knoll G a, Jaffey J, Clark HD. Combination therapy
with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a
systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8–20.
518 Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ. The role of aldosterone
blockade in murine lupus nephritis. Arthritis Res Ther 2008; 10: R5.
519 Teplitsky V, Shoenfeld Y, Tanay A. The renin-angiotensin system in lupus: physiology,
genes and practice, in animals and humans. Lupus 2006; 15: 319–325.
520 Durán-Barragán S, McGwin G, Vilá LM, Reveille JD, Alarcón GS. Angiotensinconverting
enzyme inhibitors delay the occurrence of renal involvement and are associated
with a decreased risk of disease activity in patients with systemic lupus erythematosus--
results from LUMINA (LIX): a multiethnic US cohort. Rheumatology 2008; 47: 1093–
1096.
521 Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Aymard G, Leroux G, Marra D et al.
Very low blood hydroxychloroquine concentration as an objective marker of poor
adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 821–
824.
522 Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and
tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month
prospective study. Lupus 2013; 22: 1135–1141.
523 Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J. Long-term
outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of
tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25: 3939–3948.
524 Fei Y, Wu Q, Zhang W, Chen H, Hou Y, Xu D et al. Low-dose tacrolimus in treating
lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp
Rheumatol 2013; 31: 62–68.
525 Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A et al.
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from
European cohorts. Autoimmun Rev 2012; 11: 357–364.
526 Renal disease subcomite of the American collegue of rheumatology ad hoc comite on
systemic lupus erythematosus response criteria. The American College of Rheumatology
response criteria for proliferative and membranous renal disease in systemic lupus
erythematosus clinical trials. Arthritis Rheum 2006; 54: 421–432.
527 Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M et al. European consensus
statement on the terminology used in the management of lupus glomerulonephritis. Lupus
2009; 18: 257–263.
474 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS